Personalized NK Cell Therapy in CBT
Phase 2
100
about 11 years
15–80
1 site in TX
What this study is about
This trial is testing personalized natural killer (NK) cell therapy to see if it helps patients with certain types of blood cancers or bone marrow disorders after they have received chemotherapy and a cord blood transplant. The goal is to use the patient's own NK cells, which are immune cells that can kill cancer cells, to reduce the risk of complications from the transplant.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Laboratory Biomarker Analysis
- 2.Receive Allogeneic Natural Killer Cell Line NK-92
- 3.Receive Anti-Thymocyte Globulin
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
busulfan, clofarabine, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), melphalan, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them)
injection, intravenous, infusion, injection (Injection)
Primary: Progression free survival (PFS) time in C1 patients, Progression free survival (PFS) time in C2C2 patients
Secondary: Overall survival time
radiation
Oncology